Please ensure Javascript is enabled for purposes of website accessibility

Why Sunesis Pharmaceuticals Stock Is Sinking Today

By Keith Speights – Sep 3, 2020 at 12:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker is having to take a last-resort measure to keep its shares listed on the Nasdaq stock exchange.

What happened

Shares of Sunesis Pharmaceuticals (SNSS) are sinking today, down 10.4% as of 11:35 a.m. EDT after falling as much as 19.3% earlier in the session. The decline stemmed from the company's announcement on Wednesday evening that it planned to conduct a 1-for-10 reverse stock split

So what

Reverse stock splits don't negatively impact investors. They just reduce the number of shares held while pumping up the value of each share. So why did the small biotech stock fall today? Well, reverse splits are never a good sign for a company.

Man wearing white lab coat looking through a microscope

Image source: Getty Images.

Sunesis had to move forward with this 1-for-10 reverse stock split to regain compliance with Nasdaq's $1.00 minimum bid price. The small drugmaker's shares have been trading below $0.30 for weeks and haven't topped the $1.00 threshold since March.

The only good news with Sunesis' latest move is that the alternative would have been much worse. The company would lose access to much-needed capital if its shares were delisted by the Nasdaq stock exchange.

Now what

Sunesis announced in July that it planned to review "strategic alternatives to maximize shareholder value." These alternatives included in-licensing assets, partnerships, and mergers and acquisitions. The company won't publicly disclose any progress on this front, though. The biotech stock is likely to muddle along at best until Sunesis has news to share.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sunesis Pharmaceuticals, Inc. Stock Quote
Sunesis Pharmaceuticals, Inc.
SNSS

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.